Skip to main content

Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other
Ma, J; Hegde, S; Sergeeva, M; Chakraborty, B; Wardell, SE; McDonnell, DP; Huang, PQ; Bunker, KD; Doñate, F; Lackner, MR; Samatar, AA
April 2, 2026

<p>Supplementary Table S4 shows The effect of ZN-c5 and tamoxifen on E2-suppressed genes</p>

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

DOI

Publication Date

April 2, 2026
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ma, J., Hegde, S., Sergeeva, M., Chakraborty, B., Wardell, S. E., McDonnell, D. P., … Samatar, A. A. (2026). Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. https://doi.org/10.1158/1535-7163.31923559
Ma, Jianhui, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, et al. “Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models,” April 2, 2026. https://doi.org/10.1158/1535-7163.31923559.
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA. Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

DOI

Publication Date

April 2, 2026